CN106214673A - Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder - Google Patents
Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder Download PDFInfo
- Publication number
- CN106214673A CN106214673A CN201610793620.4A CN201610793620A CN106214673A CN 106214673 A CN106214673 A CN 106214673A CN 201610793620 A CN201610793620 A CN 201610793620A CN 106214673 A CN106214673 A CN 106214673A
- Authority
- CN
- China
- Prior art keywords
- egcg
- bladder
- epigallocatechin gallate
- purposes
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Abstract
The invention discloses the new medicine use of a kind of epigallocatechin gallate (EGCG).Present invention demonstrates epigallocatechin gallate (EGCG), for tumor of bladder, there is certain curative effect, therefore can make the medicine for preventing or treat tumor of bladder using epigallocatechin gallate (EGCG) as active constituents of medicine.
Description
Technical field
The present invention relates to oncotherapy technical field, particularly relate to epigallocatechin gallate (EGCG) in preparation prevention
Or the purposes in the medicine for the treatment of tumor of bladder.
Background technology
Green tea is the conventional beverage of China, natural health, and has extensive health-care effect.EGCG
Ester (EGCG) is the tea polyphenols that in green tea, content is the highest, is also one of topmost active component in green tea, there are some researches prove tea
Polyphenol EGCG has good effects at prevention cardiovascular disease, obesity, antioxidation, the aspect such as anticancer.In the treatment of cancer and pre-
Anti-aspect, tea polyphenols EGCG, in clinical trial and inside and outside cell experiment, all shows certain curative effect.In clinical trial,
60 prostate pre-cancer pathological changes patients are divided into matched group and medication group (tea polyphenols EGCG capsule), take EGCG group after 1 year
Patient become ratio is matched group 1/10th [1] of carcinoma of prostate.Zoopery shows, EGCG can suppress Different Organs
The tumor at position occurs, such as skin, lung, liver, mammary gland, prostate, harmonization of the stomach mammary gland etc. [2].Cell experiment shows, EGCG can lead to
Cross inducing cell cycle arrest, suppression telomerase activation, suppression NF-kB activation, suppression tumor-blood-vessel growth etc., induce cancer thin
Born of the same parents' apoptosis also makes growth of cancer cells stagnate [3].Have been reported that proof EGCG can be the most widely distributed and suppress cancer at skin, food
The tissues such as pipe, stomach, intestinal, liver, prostate and organ develop, and non-evident effect [4].Tea polyphenols EGCG originates sky
So and have no side effect, there is various health care functions, be potential natural drug；And its rare report of research in bladder cancer
Road, although it has been reported that the propagation of EGCG suppression transitional cell bladder carcinoma cell line NBT-2, T24 and migration [5], but EGCG is to bladder cancer
The Study on Molecular Mechanism of SW780 and animal model checking are but not seen reported.
Summary of the invention
The present invention explores EGCG impact in propagation, migration and the apoptosis of bladder cancer；And in animal model, verify tea
The antitumor action of polyphenol EGCG also tentatively illustrates its mechanism.This, by medicine clue new for the treatment offer for bladder cancer, is also
The research and development of relevant healthcare product provide basic information and scientific guidance.
Therefore, the present invention provides epigallocatechin gallate (EGCG) at preparation prevention or the medicine for the treatment of tumor of bladder
In purposes.
Further, above-mentioned epigallocatechin gallate (EGCG) is prevented by induction apoptosis in bladder or is controlled
Treat tumor of bladder.
Further, above-mentioned epigallocatechin gallate (EGCG) is by suppressing the migration of transitional cell bladder carcinoma cell line and/or invading
Dye is prevented or treats tumor of bladder.
Further, above-mentioned epigallocatechin gallate (EGCG) by suppression transitional cell bladder carcinoma cell line propagation prevent or
Treatment tumor of bladder.
Further, above-mentioned epigallocatechin gallate (EGCG) affects PI3K/AKT pathway associated protein in bladder cancer
Expression.
Further, above-mentioned epigallocatechin gallate (EGCG) affect apoptosis-related protein Caspase-3,
The expression of Caspase-8, Caspase-9, Bcl-2 and PARP.
Further, above-mentioned epigallocatechin gallate (EGCG) reduces the expression of metastasis related protein MMP-9.
Further, above-mentioned epigallocatechin gallate (EGCG) reduces the phosphorylation level of AKT and PI3K.
Further, the expression of above-mentioned epigallocatechin gallate (EGCG) suppression PTEN.
Further, above-mentioned epigallocatechin gallate (EGCG) and pharmaceutically acceptable vehicle group synthetic drug.
Present invention demonstrates epigallocatechin gallate (EGCG), for tumor of bladder, there is certain curative effect, the most permissible
For preventing or treating tumor of bladder.
Accompanying drawing explanation
Fig. 1 shows that EGCG is to transitional cell bladder carcinoma cell line SW780 (A), 5637 (B) and the increasing of normal bladder cell SV-HUC-1 (C)
Grow inhibitory action.Abscissa is EGCG concentration；Vertical coordinate is cell survival rate.
Fig. 2 shows the EGCG apoptosis-induced effect to transitional cell bladder carcinoma cell line SW780 and 5637.
Fig. 3 shows the EGCG inhibition of metastasis effect to transitional cell bladder carcinoma cell line SW780.A, cut wound healing experiment photo；B, EGCG
Act on the scratch area block diagram of SW780 cell；C, infects the stained photographs of experiment；SW780 cellular invasion is made by D, EGCG
Experimental result.
Fig. 4 shows the EGCG inhibition of metastasis effect to transitional cell bladder carcinoma cell line 5637.A, cut wound healing experiment photo；B, EGCG make
Scratch area block diagram after 5637 cells；C, infects the stained photographs of experiment；D, EGCG are to 5637 cellular invasion effects
Experimental result.
After Fig. 5 shows immune-blotting method EGCG effect, apoptosis relevant (A) and PI3K/AKT pathway associated protein (B) exist
Expression in bladder cancer difference cell line.
Fig. 6 shows the EGCG tumor inhibition effect to mice.A, Mouse Weight variation diagram；After B, EGCG effect, blood is raw
Change alanine aminotransferase, aspartate transaminase and the change of creatine kinase in Indexs measure；In C, EGCG administration process, mice
Lotus tumor photo figure；D, mouse tumor change in volume figure；E, after experiment terminates, mouse tumor photo figure；F, mouse tumor weight post
Shape figure.
Detailed description of the invention
Present invention demonstrates epigallocatechin gallate (EGCG), for tumor of bladder, there is certain curative effect, the most permissible
Using it as active component, it is prepared as prevention or the medicine for the treatment of tumor of bladder.
In the present invention, can be with epigallocatechin gallate (EGCG) separately as medicine.Can also become with other
Being grouped into pharmaceutical composition, other composition includes: pharmaceutically acceptable substrate, carrier, additive (such as excipient, bonding
Agent, disintegrating agent, lubricant, solvent, sweetener, coloring agent, correctives, odor masking agent, surfactant, humidizer, anticorrosion
Agent, pH adjusting agent and thickening agent) etc..
In the present invention, pharmaceutically acceptable carrier, refer to nontoxic carrier, adjuvant or vehicle, it will not destroy
The pharmacological activity of the compound therewith prepared.Can be used for the pharmaceutically acceptable carrier in the present composition, assistant
Agent or vehicle include, but are not limited to: ion-exchanger, aluminium oxide, aluminium stearate, lecithin, serum albumin such as human serum
Albumin, buffer substance such as phosphoric acid salt, glycine, sorbic acid, potassium sorbate, the partial glyceride mixing of saturated vegetable fatty acid
Thing, water, salt or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloid dioxy
SiClx, magnesium trisilicate, polyvinylpyrrolidone, material based on cellulose, Polyethylene Glycol, cyclodextrin, carboxymethyl cellulose
Sodium, polyacrylate, wax class, polyethylene-polyoxypropylene-block copolymer, Polyethylene Glycol and lanoline.
In the present invention, the dosage form of medicine, such as tablet, coated tablet, powder, granule, granula subtilis, capsule, ball
Agent, liquid agent, suspensoid, Emulsion, gel, masticatory, film agent etc..
In the present invention, active component content in a medicament, it is not particularly limited, as long as playing tumor of bladder disease
Treatment or preventive effect, and suitably can determine according to preferred active component intake every day, this amount is preferably
0.0005 to 100 quality %, more preferably 0.005 to 90 quality %, and particularly preferably 0.05 to 80 quality %.
In the present invention, experimenter can be the patient suffering from tumor of bladder disease, or High risk group, such as heredity
The crowd of high occurrence risk of display, or old people (such as more than 60 years old), experimenter can also is that animal (as Canis familiaris L., cat,
Cattle, horse, pig, sheep, goat, monkey, rabbit, mice, rat, hamster etc.).
In the present invention, dosage and administration time, it is not particularly limited, can be according to patient age, patient's disease
The seriousness of shape, other conditions etc. suitably select.
Combine accompanying drawing below by specific embodiment the present invention is described in further detail.Should be appreciated that embodiment is only
It is exemplary, is not intended that limiting the scope of the invention.
I.Technology and method:
1. cell is cultivated
Bladder cancer cell lines SW780,5637 and normal bladder epithelial cell SV-HUC-1 protect purchased from American Type Culture
Center, Tibetan (American Type Culture Collection, ATCC, Manassas, USA), cell culture medium is by 90%
DMEM (Life technology, USA), the hyclone (Life technology, USA) of 10%, the glutamy of 1%-2%
Amine and the dual anti-of 0.5%-1% are made into.
2. cell proliferation detection
Use 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromide (MTT), detect cell proliferation.With containing
The culture medium of 10% tire calf serum is made into individual cells suspension, is inoculated into 96 orifice plates with 7000, every hole cell, arranges 6 again
Hole, is placed in 37 DEG C of incubators cultivation 24h；Then suck culture fluid in 96 orifice plates, add the cultivation containing variable concentrations EGCG
Liquid, is placed in 37 DEG C of incubators cultivation 24,48h.After arriving the scheduled time, in 96 orifice plates, directly add 30 μ l 5mg/ml's
MTT, continues to hatch 4h, terminates cultivating, and careful suction abandons supernatant in hole, and every hole adds dimethyl sulfoxide (DMSO) 150 μ l, and vibrations are shaken
Even；After 10min, select 540nm wavelength, enzyme-linked immunosorbent assay instrument measures the absorbance in each hole, record result, with the time
For abscissa, light absorption value is that vertical coordinate draws cell growth curve.
3. apoptosis detection
Process after cell 24h through EGCG, collect transitional cell bladder carcinoma cell line and with the PBS washing 2 times of pre-cooling, 1000rpm, 4 DEG C from
Heart 5min；Then cell is resuspended in 500 μ l buffer, adds 5 μ lAnnexin-V-FITC and 5 μ l PI (50 μ g/ml), gently
Light mixing, lucifuge, room temperature places 5min and goes to flow cytometer detection pipe again, utilize flow cytometer (EPICS, XL-4, Beckman,
CA, USA) analyze apoptosis rate.10000 cells of every part of specimen collection.
4. cell migration detection
Cell migration motor capacity is detected by cell scratch experiment.Take the logarithm the transitional cell bladder carcinoma cell line (1 × 10 of trophophase5/
Ml) it is inoculated in 24 orifice plates, and cultivates 24h at 37 DEG C of incubators.In the culture medium of serum-free after hungry cultivation 24h, with 200 μ l
Yellow rifle head cut, one, every hole, two vertical curves of horizontal line, then suck serum-free medium, and change containing variable concentrations
The fresh culture of EGCG (0,25,50,100,200 μMs), is placed in 37 DEG C of incubators cultivation.By 0,20h sampling, optical microphotograph
Mirror is taken pictures, then with the percentage ratio of TScratch software analysis wound healing area.
5. cellular invasion detection
Cell migration motor capacity is by cell transwell experiment detection.The bladder cancer that collection is in exponential phase is thin
Born of the same parents, prepare 5 × 10 by the culture medium containing 1% hyclone5The cell suspension of/ml, takes 100 μ l that is 5 × 104Cell is seeded to
Little indoor above transwell, are simultaneously introduced 100 μ l and contain the cultivation of variable concentrations EGCG (configuration of 1%FBS culture medium)
Liquid, at the lower indoor addition complete medium 500 μ l containing 10%FBS.Hatching is cultivated after 20-24h, cell with 100% methanol
Fix and use brazilwood extract dyeing, drying, observe under ordinary optical microscope and take pictures, randomly selecting 4 visuals field, use Image J
Counting wears the cell number of film.
6. immune-blotting method
Protein expression is detected with immunoblotting.After variable concentrations EGCG processes cell 24 hours, collect cell protein；
Utilizing 4 × sample-loading buffer, 100 DEG C are boiled 10min；Well-done sample is joined in 10%SDS-PAGE glue, carry out Diagnosis of Sghistosomiasis
Mark is tested；The pvdf membrane of transferring film is closed 1 hour by 10% defatted milk powder room temperature；4 DEG C of night incubation of protein antibodies, remove one and resist,
Film 10min × 3 time are washed in shaking, add the two of debita spissitudo band HRP labelling and resist, incubated at room 1 hour；Removing two to resist, shaking is washed
Film 10min × 3 time, add chemiluminescent HRP substrate nitrite ion, utilize the CCD camera lens of BD to take pictures.
7. tumor formation in nude mice
Take 6-8 week old BALB/c nude mice, 4 groups × 7, totally 28, at every nude mice dorsal sc vaccinal injection 200 μ l (2
×106) cell suspension, raise in SPF level animal experimental center.Treat that gross tumor volume reaches 80mm3After, tumor-bearing mice is randomly divided into 4
Group, negative control group (lumbar injection 0.2ml normal saline/sky), EGCG high dose group (lumbar injection 0.2ml 100mg/kg
EGCG/ days), dosage group (lumbar injection 0.2ml 50mg/kg EGCG/ days), EGCG low dose group (lumbar injection in EGCG
0.2ml 25mg/kg EGCG/ days).Use vernier caliper measurement tumor size 2 times weekly, with the long * of gross tumor volume=1/2* (wide)2
Calculate.Putting to death nude mice with de-shin after 3 weeks, take out tumor, weigh tumor weight, then recycling tumor extracts total protein and total serum IgE,
Carry out gene, protein expression analysis in tumor.
8. statistical analysis
Data analysis uses one way ANOVA statistics, and the data acquisition mean ± SD/SEM of normal distribution represents.Inspection
With P < 0.05, level represents that difference has statistical significance.
II.Experimental result:
1. the propagation of tea polyphenols EGCG suppression transitional cell bladder carcinoma cell line SW780 and 5637
After EGCG cultivates 24 or 48 hours, the proliferation activity of detection SW780,5637 and SV-HUC-1 cell.EGCG can
Substantially suppress the propagation of transitional cell bladder carcinoma cell line SW780 and 5637, and suppress in concentration and time-dependent relation (Fig. 1).Dense at EGCG
When degree is 200 μMs, the survival rate of SW780 and 5637 cells is below 20% (48h)；And it is thin at normal bladder cell SV-HUC-1
In born of the same parents, its cell survival rate reaches 90%, and EGCG selective killing transitional cell bladder carcinoma cell line is described, and under comparable sodium to normal cell also
Without obvious toxic-side effects.
2.EGCG induction transitional cell bladder carcinoma cell line SW780 and 5637 apoptosis
In order to confirm that EGCG suppression bladder cells growth, by promoting that apoptosis realizes, will process 48 through EGCG little
The apoptosis rate of the cell flow cytomery cell time after: compared to negative control group (EGCG concentration is 0), EGCG process
After the apoptosis rate of SW780 and 5637 substantially increase, and in Concentraton gradient dependence (Fig. 2), illustrate that EGCG can have
The apoptosis of effect induction cancerous cell.
3.EGCG suppresses the migration of transitional cell bladder carcinoma cell line and infects
For detection EGCG the most effectively suppress the migration of bladder cancer and infect, select cell survival rate > 80% time EGCG
Concentration, cell detects the migration of cell with scratch experiment and transwell experiment and infects after cultivating 24 hours: compared to the moon
Property matched group (EGCG concentration is 0), the cell migration of EGCG medication group and infection processs be substantially suppressed (Fig. 3 and Fig. 4), and
Present Concentraton gradient dependence, illustrate that EGCG can effectively suppress the migration of transitional cell bladder carcinoma cell line and infect when low concentration.
4.EGCG affects the expression of PI3K/AKT pathway associated protein in bladder cancer
After variable concentrations EGCG processes cell 24 hours, collect cell protein, detect protein expression with immunoblotting:
Compared to negative control group (EGCG concentration is 0), EGCG medication group can significantly affect apoptosis-related protein Caspase-3/8/9,
The expression of Bcl-2, PARP, and reduce the expression of metastasis related protein MMP-9.Additionally, EGCG can obviously reduce AKT and
The phosphorylation level of PI3K, and suppress the expression (Fig. 5) of PTEN；Illustrate that EGCG may be by affecting PI3K/AKT path at bladder
Cancer plays a role.
5.EGCG significantly inhibits the growth of tumor of bladder in mice
For detecting the antitumor efficacy of EGCG, use tumor formation in nude mice: after EGCG lumbar injection 3 weeks, find mice
Body weight and negative control group (control) do not have significant difference, and blood parameters detection shows negative control group and EGCG
Medication group is compared, and alanine aminotransferase, aspartate transaminase and creatine kinase do not have marked difference (Fig. 6 A-B)；EGCG medication
Group can effectively stop the growth of tumor, and gross tumor volume is obviously reduced, and tumor weight alleviates, and wherein EGCG high dose group effect is
Good (Fig. 6 C-F).
Above content is to combine specific embodiment further description made for the present invention, it is impossible to assert this
Bright being embodied as is confined to these explanations.For general technical staff of the technical field of the invention, do not taking off
On the premise of present inventive concept, it is also possible to make some simple deduction or replace, all should be considered as belonging to the protection of the present invention
Scope.
List of references:
1.Bettuzzi S,Brausi M,Rizzi F,Castagnetti G,Peracchia G,Corti
A.Chemoprevention of human prostate cancer by oral administration of green
tea catechins in volunteerswithhigh-grade prostate intraepithelial neoplasia:
a preliminary report from a one-year proof-of-principle study.Cancer Res
2006.66(2):1234-40.
2.Mukhtar H,Ahmad N.Tea polyphenols:prevention of cancer and
optimizing health.Am J ClinNutr 2000.71:S1698-702.
3.Gupta S,Hastak K,Afaq F,Ahmad N,Mukhtar H.Essential role of
caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor
kappa B and induction of apoptosis.Oncogene 2004.23:2507-22.
4.Singh BN,Shankar S,Srivastava RK.Green tea catechin,
epigallocatechin-3-gallate(EGCG):mechanisms,perspectives and clinical
applications.BiochemPharmacol 2011.82(12):1807-21.
5.Rieger-Christ KM,Hanley R,Lodowsky C,Bernier T,Vemulapalli P,Roth
M,Kim J,Yee AS,Le SM,Marie PJ,Libertino JA,Summerhayes IC.The green tea
compound,(-)-epigallocatechin-3-gallate downregulates N-cadherin and
suppresses migration of bladder carcinoma cells.J Cell Biochem 2007.102(2):
377-88.
Claims (10)
1. epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder.
Purposes the most according to claim 1, it is characterised in that described epigallocatechin gallate (EGCG) is by induction
Apoptosis in bladder prevents or treats tumor of bladder.
Purposes the most according to claim 1, it is characterised in that described epigallocatechin gallate (EGCG) is by suppression
The migration of transitional cell bladder carcinoma cell line and/or infect and prevent or treat tumor of bladder.
Purposes the most according to claim 1, it is characterised in that described epigallocatechin gallate (EGCG) is by suppression
The propagation of transitional cell bladder carcinoma cell line is prevented or treats tumor of bladder.
Purposes the most according to claim 1, it is characterised in that described epigallocatechin gallate (EGCG) affects bladder
The expression of PI3K/AKT pathway associated protein in cancer.
Purposes the most according to claim 5, it is characterised in that described epigallocatechin gallate (EGCG) affects apoptosis
Associated protein Caspase-3, the expression of Caspase-8, Caspase-9, Bcl-2 and PARP.
Purposes the most according to claim 5, it is characterised in that described epigallocatechin gallate (EGCG) reduces transfer
The expression of associated protein MMP-9.
Purposes the most according to claim 5, it is characterised in that described epigallocatechin gallate (EGCG) reduces AKT
Phosphorylation level with PI3K.
Purposes the most according to claim 5, it is characterised in that described epigallocatechin gallate (EGCG) suppression PTEN
Expression.
10. according to the purposes described in any one of claim 1-9, it is characterised in that described EGCG
Ester and pharmaceutically acceptable vehicle group synthetic drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610793620.4A CN106214673A (en) | 2016-08-31 | 2016-08-31 | Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610793620.4A CN106214673A (en) | 2016-08-31 | 2016-08-31 | Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214673A true CN106214673A (en) | 2016-12-14 |
Family
ID=58074222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610793620.4A Pending CN106214673A (en) | 2016-08-31 | 2016-08-31 | Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214673A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745333A (en) * | 2017-11-06 | 2019-05-14 | 深圳市龙华区人民医院 | A kind of pharmaceutical composition and its application for bladder cancer treatment |
| WO2020015683A1 (en) * | 2018-07-18 | 2020-01-23 | Shanghaitech University | Functionality independent labeling of organic compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151582A1 (en) * | 2000-10-11 | 2002-10-17 | Dou Q. Ping | Tea polyphenol esters and analogs thereof for cancer prevention and treatment |
| CN104023713A (en) * | 2011-09-07 | 2014-09-03 | 德国癌症研究中心 | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
-
2016
- 2016-08-31 CN CN201610793620.4A patent/CN106214673A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151582A1 (en) * | 2000-10-11 | 2002-10-17 | Dou Q. Ping | Tea polyphenol esters and analogs thereof for cancer prevention and treatment |
| CN104023713A (en) * | 2011-09-07 | 2014-09-03 | 德国癌症研究中心 | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
Non-Patent Citations (4)
| Title |
|---|
| BRIAN J.PHILIPS,等: ""Induction of apoptosis in human bladder cancer cells by green tea catechins"", 《BIOMEDICAL RESEARCH》 * |
| 王田，等: "茶多酚对膀胱肿瘤细胞端粒酶活性的影响", 《现代泌尿外科杂志》 * |
| 秦杰 等: ""表没食子儿茶素没食子酸酯对人膀胱癌T24细胞凋亡的影响"", 《杭州师范学院学报(医学版)》 * |
| 秦杰 等: "表没食子儿茶素没食子酸酯对人膀胱癌T24细胞增殖的影响", 《杭州师范学院学报(医学版)》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745333A (en) * | 2017-11-06 | 2019-05-14 | 深圳市龙华区人民医院 | A kind of pharmaceutical composition and its application for bladder cancer treatment |
| CN109745333B (en) * | 2017-11-06 | 2021-05-28 | 深圳市龙华区人民医院 | Pharmaceutical composition for treating bladder cancer and application thereof |
| WO2020015683A1 (en) * | 2018-07-18 | 2020-01-23 | Shanghaitech University | Functionality independent labeling of organic compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosillo et al. | Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats | |
| Lu et al. | Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin | |
| Trudel et al. | Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies | |
| Zhang et al. | Bisperoxovandium (pyridin‐2‐squaramide) targets both PTEN and ERK1/2 to confer neuroprotection | |
| Hong et al. | Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells | |
| Lu et al. | Inhibitory effect of Erinacines A on the growth of DLD-1 colorectal cancer cells is induced by generation of reactive oxygen species and activation of p70S6K and p21 | |
| Wu et al. | Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation | |
| Song et al. | ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro | |
| Zhao et al. | The induction of apoptosis and autophagy in human hepatoma SMMC-7721 cells by combined treatment with vitamin C and polysaccharides extracted from Grifola frondosa | |
| Husari et al. | Pomegranate juice prevents the formation of lung nodules secondary to chronic cigarette smoke exposure in an animal model | |
| Wu et al. | Yiqi Huayu Jiedu decoction inhibits the invasion and metastasis of gastric cancer cells through TGF-β/Smad pathway | |
| Wang et al. | A case-control study of stomach cancer in relation to Camellia sinensis in China | |
| CN106214673A (en) | Epigallocatechin gallate (EGCG) purposes in the medicine of preparation prevention or treatment tumor of bladder | |
| CN109568299A (en) | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations | |
| Kawashima et al. | Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon | |
| CN102106914A (en) | Medicament for treating infectious diseases, preparation method and application thereof | |
| He et al. | Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K/Akt/mTOR pathway | |
| Park et al. | Anti-tumor effects of the ethanolic extract of Trichosanthes kirilowii seeds in colorectal cancer | |
| CN109745333A (en) | A kind of pharmaceutical composition and its application for bladder cancer treatment | |
| CN114306309B (en) | Use of naphthyl substituted trifluoromethyl benzocyclopentanone in cancer treatment | |
| CN109602752A (en) | Triptolide is in induction cancer cell autophagy and hdac inhibitor is cooperateed with to treat the application in tumour | |
| CN103142774A (en) | Application of total saponin extract of lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma | |
| CN110051734B (en) | Pharmaceutical composition for resisting colon cancer related to colitis and application thereof | |
| CN113384591A (en) | Combined drug of trametes acid and sorafenib and application of combined drug in preparation of antitumor drug | |
| CN102440987B (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161214 |
|
| WD01 | Invention patent application deemed withdrawn after publication |